AIVITA Biomedical signs distribution agreement with Lacore Labs

AIVITA Biomedical has signed an agreement with Lacore Laboratories for the distribution of a new line of skincare products in Hong Kong, Taiwan, Singapore, Malaysia, and Mainland China.

Developed using Aivita’s proprietary skincare technology, the new line will be distributed by Lacore’s subsidiary Generation New Online.

AIVITA Biomedical chairman and CEO Dr Hans Keirstead said: “Lacore brings unique capabilities to AIVITA, including its cultural knowledge of product preferences and its distribution prowess throughout Asia. We’re thrilled to be bringing our revolutionary active technology to consumers throughout the world.”

The company’s multi-functional ingredient complex and delivery system has been designed to capture the natural cell messaging system and ingredients of skin stem cells.

With the deal, AIVITA will be able to support its clinical development, including a platform cancer immunotherapy.

US-based AIVITA Biomedical is involved in the advancement of commercial and clinical-stage programmes using curative and regenerative medicines.

The company’s expertise in stem cell growth and directed high-purity differentiation is used to enable manufacturing systems to support its commercial line of skincare products.